How State Prescription Drug Affordability Boards Could Affect 340B Savings
As more states move to implement prescription drug affordability boards (PDABs), some 340B experts are raising concerns that upper payment limits (UPLs) on medications could reduce 340B savings for covered entities and create implementation challenges.
Read more
FLORIDA GROUP BEHIND ANTI-340B ADS in ILLINOIS, VIRGINIA
A Florida nonprofit that says it’s “dedicated to standing against corporate influence” but does not disclose its donors spent nearly $200,000 on ads criticizing 340B providers in two state capitals where pharmaceutical companies have fought to defeat contract pharmacy access bills in early 2026, according to FCC filings and copies of the ads obtained by 340B Report.
Read more
DARK MONEY PRESSURES GOP LAWMAKERS TO BACK REBATES
A dark money group with undisclosed donors and direct ties to a Washington, D.C. lobbying firm launched a new campaign pressuring congressional Republicans to support 340B rebate models, 340B Report uncovered.
Read more
"Oklahoma has finally taken a stand"
State lawmakers in deep red Oklahoma defied their Republican governor and fought drug industry lobbying, dark money ad campaigns and social media pressure from national conservative influencers to enact a 340B contract pharmacy protection law. In this in-depth report, 340B Report spoke to lawmakers and advocates to unpack the years-long fight behind the legislation, the shadowy political forces that tried to kill it and the coalition of provider and pharmacist groups that ultimately turned the tide.
Read more
"I don't want to go through this nightmare"
A two-part series on the growing frustrations safety net providers face in restoring access to 340B pricing in the contract pharmacy setting. Part 1 provides important background on the challenges that covered entities face and looks at the origins of 340B ESP, the clearinghouse used by 16 of the 18 drug manufacturers restricting 340B pricing at contract pharmacies. Part 2 focuses on the perspective of 340B providers trying to jump through what appear to be, in many cases, endless hoops to try to restore 340B pricing. We also reached out to other key players in the pharmaceutical supply chain.
Read more
Bristol Myers Squibb
Our seven-part investigative series takes an in-depth look into a question often asked by 340B providers: Why can’t they access 340B pricing on some of Bristol Myers Squibb/Celgene’s most expensive cancer drugs? Approximately six-months after our series, which included never-before seen communications between the government and the pharmaceutical company, BMS made a major change. Now over a thousand hospitals have access to significant discounts on these drug products. Serious questions remain about allegations of drug manufacturer fraud and what took so long for BMS’s policy to change.
Read moreGENESIS HEALTHCARE V. BECERRA
A two-part deep dive into one of the most important and contentious areas of the 340B program. While much of the 340B community’s attention has been focused on the contract pharmacy suits winding through the federal court system, there is other activity that the federal court system is grappling with that one could argue is equally or even more important. A federal appeals court is his hearing arguments challenging one of the 340B program’s bedrock principles—the definition of a “patient” eligible to receive 340B drugs.340B Report takes a close look at the groundbreaking case’s influence Read more
